MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer
Portfolio Pulse from Nabaparna Bhattacharya
MAIA Biotechnology has received FDA clearance for its Investigational New Drug application for THIO, a treatment for non-small-cell-lung-cancer. THIO will be evaluated in the US as part of the ongoing THIO-101 global phase 2 clinical trial. The drug is being tested with Regeneron Pharmaceuticals' cemiplimab to evaluate anti-tumor activity and immune response in patients. MAIA recently approved a share repurchase program of up to $800,000 of its Class A common stock through September 2024.
October 03, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' cemiplimab is being tested with MAIA Biotechnology's THIO to evaluate anti-tumor activity and immune response in lung cancer patients.
While the news is positive for Regeneron, as it indicates potential new uses for cemiplimab, the impact on the stock is likely to be neutral in the short term as the outcome of the tests is still uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
MAIA Biotechnology has received FDA clearance for its Investigational New Drug application for THIO, a lung cancer treatment. The company also approved a share repurchase program.
The FDA clearance for THIO is a significant milestone for MAIA, potentially leading to increased investor confidence. The share repurchase program also indicates the company's confidence in its stock, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100